MetaVia Inc.
MTVAHealthcareNASDAQBiotechnology · Last scanned Oct 21, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 20
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company carries a $8.5M market cap, placing it firmly in the micro-cap category. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Market Cap
$8.5M
Beta
0.96
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-3.65
EPS (Fwd)
—
ROE
-175.7%
ROA
-58.8%
Cash
$12.6M
Total Debt
$177,000
Free CF
-$11.1M
52W Change
-87.8%
Annual Financials
Cash vs Debt
Where MTVA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MTVA finished 24.54% below its 150-day moving average ($1.63) and 38.19% below its 200-day moving average ($1.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MTVA overbought or oversold?
At the October 20, 2026 close, MTVA's RSI(14) was 17.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $12.6M in cash and $177K in debt, MTVA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$11.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -175.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing MTVA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.